Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
Epidemiological evidence suggests that by the age of 40 years, all individuals with Down syndrome (DS) have Alzheimer’s disease (AD) neuropathology. Clinical diagnosis of dementia by cognitive assessment is complex in these patients due to the pre-existing and varying intellectual disability, which...
Main Authors: | Laia Montoliu-Gaya, Andre Strydom, Kaj Blennow, Henrik Zetterberg, Nicholas James Ashton |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/16/3639 |
Similar Items
-
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
by: Sebastian Palmqvist, et al.
Published: (2019-12-01) -
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
by: Martí Colom-Cadena, et al.
Published: (2020-03-01) -
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
by: Alain D. Dekker, et al.
Published: (2017-01-01) -
Biomarkers in Alzheimer’s disease
by: Mario eRiverol, et al.
Published: (2011-07-01) -
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
by: Rachel L. Henson, et al.
Published: (2020-01-01)